Daratumumab, lenalidomide, and dexamethasone for multiple myeloma
The addition of daratumumab to lenalidomide and dexamethasone resulted in superior response rate and progression-free survival, as compared with lenalidomide and dexamethasone alone, at a cost of more frequent neutropenia and infusion reactions.
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
6 October 2016
|
| In: |
The New England journal of medicine
Year: 2016, Jahrgang: 375, Heft: 14, Pages: 1319-1331 |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMoa1607751 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1056/NEJMoa1607751
|
| Verfasserangaben: | Meletios A. Dimopoulos, Albert Oriol, Hareth Nahi, Jesus San-Miguel, Nizar J. Bahlis, Saad Z. Usmani, Neil Rabin, Robert Z. Orlowski, Mieczyslaw Komarnicki, Kenshi Suzuki, Torben Plesner, Sung-Soo Yoon, Dina Ben Yehuda, Paul G. Richardson, Hartmut Goldschmidt, Donna Reece, Steen Lisby, Nushmia Z. Khokhar, Lisa O’Rourke, Christopher Chiu, Xiang Qin, Mary Guckert, Tahamtan Ahmadi, Philippe Moreau |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1565103203 | ||
| 003 | DE-627 | ||
| 005 | 20230427142107.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 171107s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa1607751 |2 doi | |
| 035 | |a (DE-627)1565103203 | ||
| 035 | |a (DE-576)495103209 | ||
| 035 | |a (DE-599)BSZ495103209 | ||
| 035 | |a (OCoLC)1340981427 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Dimopoulos, Meletios A. |e VerfasserIn |0 (DE-588)111795188X |0 (DE-627)871747634 |0 (DE-576)479413746 |4 aut | |
| 245 | 1 | 0 | |a Daratumumab, lenalidomide, and dexamethasone for multiple myeloma |c Meletios A. Dimopoulos, Albert Oriol, Hareth Nahi, Jesus San-Miguel, Nizar J. Bahlis, Saad Z. Usmani, Neil Rabin, Robert Z. Orlowski, Mieczyslaw Komarnicki, Kenshi Suzuki, Torben Plesner, Sung-Soo Yoon, Dina Ben Yehuda, Paul G. Richardson, Hartmut Goldschmidt, Donna Reece, Steen Lisby, Nushmia Z. Khokhar, Lisa O’Rourke, Christopher Chiu, Xiang Qin, Mary Guckert, Tahamtan Ahmadi, Philippe Moreau |
| 264 | 1 | |c 6 October 2016 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 07.11.2017 | ||
| 520 | |a The addition of daratumumab to lenalidomide and dexamethasone resulted in superior response rate and progression-free survival, as compared with lenalidomide and dexamethasone alone, at a cost of more frequent neutropenia and infusion reactions. | ||
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d Waltham, Mass. : MMS, 1928 |g 375(2016), 14, Seite 1319-1331 |h Online-Ressource |w (DE-627)266889484 |w (DE-600)1468837-2 |w (DE-576)075962454 |x 1533-4406 |7 nnas |a Daratumumab, lenalidomide, and dexamethasone for multiple myeloma |
| 773 | 1 | 8 | |g volume:375 |g year:2016 |g number:14 |g pages:1319-1331 |g extent:13 |a Daratumumab, lenalidomide, and dexamethasone for multiple myeloma |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa1607751 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa1607751 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20171107 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 15 | ||
| 999 | |a KXP-PPN1565103203 |e 2986716237 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title_sort":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma"}],"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"6 October 2016"}],"note":["Gesehen am 07.11.2017"],"id":{"eki":["1565103203"],"doi":["10.1056/NEJMoa1607751"]},"relHost":[{"title":[{"title_sort":"New England journal of medicine","subtitle":"NEJM","title":"The New England journal of medicine"}],"pubHistory":["198.1928 -"],"note":["Gesehen am 04.08.25"],"origin":[{"publisherPlace":"Waltham, Mass. ; Boston, Mass.","dateIssuedKey":"1928","publisher":"MMS ; MMS","dateIssuedDisp":"1928-"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Daratumumab, lenalidomide, and dexamethasone for multiple myelomaThe New England journal of medicine","recId":"266889484","physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["Massachusetts Medical Society"]},"id":{"eki":["266889484"],"issn":["1533-4406"],"zdb":["1468837-2"]},"corporate":[{"role":"isb","display":"Massachusetts Medical Society"}],"language":["eng"],"part":{"volume":"375","extent":"13","pages":"1319-1331","year":"2016","text":"375(2016), 14, Seite 1319-1331","issue":"14"},"titleAlt":[{"title":"NEJM"}]}],"recId":"1565103203","physDesc":[{"extent":"13 S."}],"name":{"displayForm":["Meletios A. Dimopoulos, Albert Oriol, Hareth Nahi, Jesus San-Miguel, Nizar J. Bahlis, Saad Z. Usmani, Neil Rabin, Robert Z. Orlowski, Mieczyslaw Komarnicki, Kenshi Suzuki, Torben Plesner, Sung-Soo Yoon, Dina Ben Yehuda, Paul G. Richardson, Hartmut Goldschmidt, Donna Reece, Steen Lisby, Nushmia Z. Khokhar, Lisa O’Rourke, Christopher Chiu, Xiang Qin, Mary Guckert, Tahamtan Ahmadi, Philippe Moreau"]},"person":[{"display":"Dimopoulos, Meletios A.","family":"Dimopoulos","given":"Meletios A.","role":"aut"},{"display":"Goldschmidt, Hartmut","family":"Goldschmidt","role":"aut","given":"Hartmut"}],"language":["eng"]} | ||
| SRT | |a DIMOPOULOSDARATUMUMA6201 | ||